New weekly shot aims to tackle high blood pressure and obesity together

NCT ID NCT07469800

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests a drug called IBI362 in people with mild to moderate high blood pressure who are also overweight or obese. Participants receive weekly injections of either the drug or a placebo for 48 weeks. The main goal is to see if IBI362 lowers blood pressure more than placebo at 16 weeks, with additional checks on weight loss and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI362 (a drug injected under the skin once a week)
What this could lead to: If it works, this could offer a new treatment option that lowers both blood pressure and body weight in people with hypertension and overweight or obesity.
What could go wrong: This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results may not apply to everyone with hypertension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSIVE OBESITY OVERWEIGHT

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.